Enanta Pharmaceuticals Inc (ENTA) Stock Price & Analysis
Enanta Pharmaceuticals Inc (ENTA) rose 2.53% to USD 11.35 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
ENTA last closed at USD 11.07; the session ranged USD 11.19–11.55 on volume of 116,581 shares. Market capitalization is $330.04M, with a 52-week range of USD 6.44–17.15 (NMS). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 11.35 |
|---|---|
| Change | ▲ 2.53% (up) |
| Previous Close | USD 11.07 |
| Open | USD 11.23 |
| Day Range | USD 11.19 – 11.55 |
| 52-Week Range | USD 6.44 – 17.15 |
| Volume | 116,581 shares |
| Market Cap | $330.04M |
| Exchange | NMS |
Technical Analysis (ENTA)
Nexqual's technical model rates ENTA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.13 (neutral) |
| vs SMA50 | Below (USD 13.53) |
| MACD | -0.71 (negative) |
Analyst Ratings (ENTA)
Wall Street analysts rate ENTA "None" based on 7 analysts, with a mean price target of USD 20.14 (range USD 14–28), per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 20.14 |
| High Target | USD 28 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ENTA)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.45 |
| Revenue Estimate | $17.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.45 vs est -0.49 ▲ beat |
| 2025-12-31 | USD -0.42 vs est -0.88 ▲ beat |
| 2025-09-30 | USD -0.87 vs est -1.01 ▲ beat |
| 2025-06-30 | USD -0.85 vs est -0.89 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (ENTA)
| Total Revenue | $69.21M |
|---|---|
| Revenue Growth (YoY) | +15.00% |
| Gross Margin | +100.00% |
| Operating Margin | -69.07% |
| Profit Margin | -89.55% |
| ROE | -59.00% |
| Debt / Equity | 160.07 |
| Current Ratio | 3.84 |
| Total Cash | $163.77M |
| Total Debt | $186.62M |
| Free Cash Flow | $7.69M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (ENTA)
Nexqual rates Enanta Pharmaceuticals Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Weak — Operating margin -69% |
| Balance Sheet | Weak — $164M cash vs $187M debt |
| Cash Flow | Solid — FCF $8M, 12% margin |
| Efficiency | Critical — ROE -59%, ROA -11.8% |
Ownership (ENTA)
| Insider Ownership | +4.68% |
|---|---|
| Institutional Ownership | +92.82% |
| Shares Outstanding | 29.08M |
| Float | 20.06M |
| Short % of Float | +9.36% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (ENTA)
Enanta Pharmaceuticals Inc is led by Jay R. Luly (age 69), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:23 UTC.
| President, CEO & Director | Jay R. Luly (age 69) |
|---|---|
| Chief Scientific Officer | Yat Sun Or (age 73) |
| Executive Director of Accounting, Controller & Interim Principal Accounting Officer | Kathleen S. Capps (age 40) |
| Executive Director of Investor Relations & Corporate Communications | Jennifer Viera |
| Chief Product Strategy Officer | Tara Lynn Kieffer (age 47) |
Major Backers & Investors (ENTA)
Notable institutional backers of Enanta Pharmaceuticals Inc include Janus Henderson Group PLC, Farallon Capital Management LLC, Krensavage Asset Management, LLC, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 13.01% |
| Farallon Capital Management LLC | 9.88% |
| Krensavage Asset Management, LLC | 9.86% |
| Deep Track Capital, Lp | 6.73% |
| Spruce Street Capital LP | 3.21% |
| Acadian Asset Management. LLC | 3.03% |
| Millennium Management | 3.03% |
| Fidelity | 1.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.12% |
| Vanguard Group | 12.86% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
From Enanta Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2025-11-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
- It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XNCR | Xencor, Inc. | USD 11.89 | ▲ 1.02% |
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| AGIO | Agios Pharmaceuticals, Inc. | USD 28.14 | ▼ 0.53% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.